Oncotelic Therapeutics (OTLC) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free OTLC Stock Alerts $0.04 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 3:57 AM | finance.yahoo.comONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024March 25, 2024 | finance.yahoo.comLinkage of Cancer and Lupus in Gliomas PatientsMarch 25, 2024 | globenewswire.comLinkage of Cancer and Lupus in Gliomas PatientsMarch 4, 2024 | globenewswire.comInvitation to Participate in STOP-PC Clinical TrialFebruary 22, 2024 | benzinga.comOncotelic Therapeutics Stock (OTC:OTLC) Earnings Dates and Earning CallsFebruary 3, 2024 | msn.comOncotelic Therapeutics Strikes Material Definitive Legal AgreementJanuary 23, 2024 | morningstar.comLineage Cell Therapeutics Inc LCTXDecember 18, 2023 | finance.yahoo.comOncotelic Therapeutics Announces Opening of GMP Manufacturing PlantNovember 15, 2023 | finanznachrichten.deOncotelic Therapeutics, Inc.: Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial ResultsNovember 15, 2023 | msn.comOncotelic Therapeutics reports Q3 resultsNovember 15, 2023 | finance.yahoo.comOncotelic Reports Q3 2023 Compared to Q3 2022 Financial ResultsSeptember 11, 2023 | benzinga.comThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The ChargeSeptember 11, 2023 | benzinga.comThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The ChargeAugust 25, 2023 | finance.yahoo.comOncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023August 23, 2023 | finance.yahoo.comSapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic CancerMay 16, 2023 | finance.yahoo.comOncotelic Participating at 2023 BIO International ConventionApril 24, 2023 | technews.tmcnet.comOncotelic Launches PDAO SEC ChatbotApril 20, 2023 | seekingalpha.comOncotelic Therapeutics reports FY resultsApril 19, 2023 | finance.yahoo.comOncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model TechnologyMarch 13, 2023 | technews.tmcnet.comHigh Intra-Tumor TGF-ß2 Predicts Poor Survival in Pediatric Cancer of the BrainstemFebruary 15, 2023 | seekingalpha.comOTLC Oncotelic Therapeutics, Inc.February 6, 2023 | finance.yahoo.comOncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell CancerJanuary 25, 2023 | finance.yahoo.comOncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic CancerDecember 28, 2022 | finance.yahoo.comOncotelic Issues Year End Message to ShareholdersNovember 8, 2022 | finance.yahoo.comOncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric GliomasSeptember 28, 2022 | finance.yahoo.comOncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual MeetingSeptember 16, 2022 | sg.finance.yahoo.comOncotelic Therapeutics, Inc. (OTLC)September 14, 2022 | finance.yahoo.comOncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual MeetingAugust 23, 2022 | seekingalpha.comOncotelic Therapeutics reports Q2 resultsAugust 22, 2022 | finance.yahoo.comONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTSAugust 17, 2022 | finance.yahoo.comOncotelic Participating at Biotechgate Digital PartneringJuly 12, 2022 | finance.yahoo.comOncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic CancerMay 25, 2022 | seekingalpha.comOncotelic gets FDA nod for mid-stage trial design for lead asset and Keytruda comboMay 25, 2022 | finance.yahoo.comOncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)May 23, 2022 | finance.yahoo.comONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATEMay 11, 2022 | finance.yahoo.comONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION WITH CHECKPOINT INHIBITORSMay 3, 2022 | finance.yahoo.comOncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical OfficerApril 18, 2022 | finance.yahoo.comONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED TO YE 2020, PRODUCT DEVELOPMET INITIATIVES AND CORPORATE UPDATEMarch 10, 2022 | finance.yahoo.comOncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual Meeting 2022March 3, 2022 | finance.yahoo.comDr. Anthony E. Maida will be presenting at the Marcus Evans Evolution SummitFebruary 24, 2022 | finance.yahoo.comOncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor ConferenceJanuary 19, 2022 | finance.yahoo.comOncotelic Presenting at BiotechGate Digital PartneringJanuary 5, 2022 | finance.yahoo.comOncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for MelanomaDecember 16, 2021 | stockhouse.comOncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022December 14, 2021 | markets.businessinsider.comDGAP-News: Oncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-ß for Immuno-Oncology Drug Development Summit in January 2022December 14, 2021 | finance.yahoo.comOncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022December 1, 2021 | finance.yahoo.comOncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA® for MesotheliomaNovember 16, 2021 | finance.yahoo.comOncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor CancersOctober 20, 2021 | finance.yahoo.comONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS INCLUDING C001 COVID STUDYOctober 4, 2021 | finance.yahoo.comONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION. Get Oncotelic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLC and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide OTLC Media Mentions By Week OTLC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLC News Sentiment▼0.860.55▲Average Medical News Sentiment OTLC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLC Articles This Week▼20▲OTLC Articles Average Week Get Oncotelic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EDSA News HUGE News CRPOF News COCP News PIRS News AVTX News RDHL News TNXP News LTUS News VAXX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:OTLC) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsHow Biden has already won 2024Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis is bad news for Biden…The Freeport Society348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncotelic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
